CL2019001419A1 - Derivado de pirido[3,4–d]pirimidina y su sal farmacéuticamente aceptable. - Google Patents

Derivado de pirido[3,4–d]pirimidina y su sal farmacéuticamente aceptable.

Info

Publication number
CL2019001419A1
CL2019001419A1 CL2019001419A CL2019001419A CL2019001419A1 CL 2019001419 A1 CL2019001419 A1 CL 2019001419A1 CL 2019001419 A CL2019001419 A CL 2019001419A CL 2019001419 A CL2019001419 A CL 2019001419A CL 2019001419 A1 CL2019001419 A1 CL 2019001419A1
Authority
CL
Chile
Prior art keywords
pharmaceutically acceptable
pyrimidine
acceptable salt
pyrido
derivative
Prior art date
Application number
CL2019001419A
Other languages
English (en)
Inventor
Kosuke Sasaki
Tsuyoshi Mizuno
Tomohiro Shimada
Gen Unoki
Akinobu Maruyama
Takuya Yokosaka
Hiroshi Takahashi
Kyohei Horie
Yuri Sakai
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of CL2019001419A1 publication Critical patent/CL2019001419A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

UN OBJETO DE LA PRESENTE INVENCIÓN ES PROPORCIONAR UN COMPUESTO QUE EXHIBE UNA ACTIVIDAD INHIBIDORA DE CDK4/6 SUPERIOR. LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO REPRESENTADO POR LA FÓRMULA (I) O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES.
CL2019001419A 2016-11-28 2019-05-24 Derivado de pirido[3,4–d]pirimidina y su sal farmacéuticamente aceptable. CL2019001419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016229969 2016-11-28

Publications (1)

Publication Number Publication Date
CL2019001419A1 true CL2019001419A1 (es) 2019-08-30

Family

ID=62194988

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001419A CL2019001419A1 (es) 2016-11-28 2019-05-24 Derivado de pirido[3,4–d]pirimidina y su sal farmacéuticamente aceptable.

Country Status (28)

Country Link
US (1) US11084814B2 (es)
EP (1) EP3546458B1 (es)
JP (1) JP6785876B2 (es)
KR (1) KR102290815B1 (es)
CN (1) CN110036012B (es)
AR (1) AR110238A1 (es)
AU (1) AU2017364807B2 (es)
BR (1) BR112019010674A2 (es)
CA (1) CA3043561A1 (es)
CL (1) CL2019001419A1 (es)
CO (1) CO2019005514A2 (es)
CY (1) CY1123850T1 (es)
DK (1) DK3546458T3 (es)
ES (1) ES2852123T3 (es)
HR (1) HRP20210285T1 (es)
HU (1) HUE053220T2 (es)
IL (1) IL266312B (es)
LT (1) LT3546458T (es)
MX (1) MX2019005803A (es)
MY (1) MY196497A (es)
PH (1) PH12019501171A1 (es)
PL (1) PL3546458T3 (es)
PT (1) PT3546458T (es)
SA (1) SA519401827B1 (es)
SI (1) SI3546458T1 (es)
TW (1) TWI799399B (es)
WO (1) WO2018097297A1 (es)
ZA (1) ZA201902893B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230303564A1 (en) * 2020-08-17 2023-09-28 Medshine Discovery Inc. Pyrimidine ring compound
CN113636973B (zh) * 2021-09-07 2023-04-07 山东铂源药业股份有限公司 一种4-(6-氨基吡啶-3-基)哌嗪-1-羧酸叔丁酯的工业化制备方法
WO2023155841A1 (zh) * 2022-02-16 2023-08-24 南京明德新药研发有限公司 嘧啶并环类化合物的盐型、晶型
WO2024020419A1 (en) * 2022-07-18 2024-01-25 Iambic Therapeutics, Inc. Aza-quinazoline compounds and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102295643B (zh) 2002-01-22 2013-12-04 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
EP2716643A1 (en) 2008-08-22 2014-04-09 Novartis AG Pyrrolopyrimidine compounds and their uses
CN102231984A (zh) 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
BR112013007506A2 (pt) 2010-09-01 2016-07-12 Genentech Inc piridinonas/pirazinonas - métodos de criação e de uso
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
WO2014183520A1 (zh) * 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
KR102339228B1 (ko) 2013-08-23 2021-12-13 뉴파마, 인크. 특정 화학 물질, 조성물, 및 방법
EP3052573A4 (en) * 2013-09-30 2017-03-22 CertainTeed Corporation Stain repellent and voc eliminating coatings and use thereof
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
US9828373B2 (en) * 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
MX2017015277A (es) 2015-05-29 2018-02-19 Teijin Pharma Ltd Derivado de pirido[3,4-d]pirimidina y sal farmaceuticamente aceptable de este.

Also Published As

Publication number Publication date
PT3546458T (pt) 2021-02-25
EP3546458B1 (en) 2021-01-06
CO2019005514A2 (es) 2019-07-31
US11084814B2 (en) 2021-08-10
SA519401827B1 (ar) 2022-07-28
US20190367510A1 (en) 2019-12-05
PH12019501171A1 (en) 2021-02-08
CY1123850T1 (el) 2022-05-27
PL3546458T3 (pl) 2021-06-14
AU2017364807A1 (en) 2019-05-16
KR102290815B1 (ko) 2021-08-18
AR110238A1 (es) 2019-03-13
ES2852123T3 (es) 2021-09-13
WO2018097297A1 (ja) 2018-05-31
IL266312A (en) 2019-06-30
MX2019005803A (es) 2019-09-10
DK3546458T3 (da) 2021-02-22
IL266312B (en) 2021-08-31
SI3546458T1 (sl) 2021-03-31
AU2017364807B2 (en) 2021-05-13
CN110036012B (zh) 2022-05-10
RU2019116137A3 (es) 2021-08-13
HRP20210285T1 (hr) 2021-04-02
EP3546458A1 (en) 2019-10-02
JP6785876B2 (ja) 2020-11-18
MY196497A (en) 2023-04-17
BR112019010674A2 (pt) 2019-10-01
KR20190066631A (ko) 2019-06-13
JPWO2018097297A1 (ja) 2019-06-24
HUE053220T2 (hu) 2021-06-28
TWI799399B (zh) 2023-04-21
RU2019116137A (ru) 2020-11-27
CA3043561A1 (en) 2018-05-31
CN110036012A (zh) 2019-07-19
ZA201902893B (en) 2020-01-29
EP3546458A4 (en) 2019-10-09
TW201831476A (zh) 2018-09-01
LT3546458T (lt) 2021-05-10

Similar Documents

Publication Publication Date Title
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
CL2019001419A1 (es) Derivado de pirido[3,4–d]pirimidina y su sal farmacéuticamente aceptable.
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
CO6852096A2 (es) Métodos plaguicidasque utilizan compuestos de 3-piridil tiazol sustituidos y derivados para combatir las plagas de animales i
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
BR112017023540A2 (pt) síntese de derivados de 1 h-pirrolo[2,3-b]piridin que modulam quinases
CO2018001268A2 (es) Derivados de heteroarilo como inhibidores de parp
BR112016024545A2 (pt) derivados de pirazolo pirimidina e seu uso como inibidores de malt1
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
BR112016029825A2 (pt) composto
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
CL2020000376A1 (es) Compuesto pentacíclico.
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
CL2018001067A1 (es) Compuesto piranodipiridínico.
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
MX2018002018A (es) Derivado de urea y uso del mismo.
CR20160029A (es) Compuestos de pirimidino sustituido y derivados para combatir plagas de animales
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
AR092772A1 (es) Derivado de 7-azaindol
CR20170058A (es) Un derivado de tetrahidropirrolo[3,4-d][1,3]tiazina como inhibidor de bace